The report titled The Urgency of Now: AIDS at a Crossroads, demonstrates the HIV response is at a crossroads: success or failure will be determined by which path leaders take. The report shows that the decisions leaders make this year will determine whether AIDS is ended as a public health threat by 2030. Taking the wrong path, by limiting resourcing or clamping down on human rights, would lead the pandemic to continue to grow, costing millions more lives and undermining global health security.

Since HIV was first identified in the early 1980s, we have had numerous scientific advancements to improve HIV prevention and treatment. However, there are still 38 million people currently living with HIV, and a proportion of them have developed Acquired Immunodeficiency Syndrome (AIDS). The main issue with HIV and AIDs is inequalities: the communities affected are disproportionately distributed among the Global South. World AIDS Day takes place every year on the 1st of December and was founded in 1988 — making it the first global health day to be established. This year, the theme of World AIDS Day is equality. Tackling the inequalities surrounding HIV testing, prevention, care, and stigma among marginalized populations is the only way to not fall behind the targets of the third sustainable development goal of ending the HIV/AIDS epidemic by 2030.

The 2023 annual meeting of the World Health Organization (WHO) Clinical Consortium on Healthy Ageing (CCHA) took place in Geneva, Switzerland in December 2023. It was the group’s ninth gathering. The meeting consisted of seven panels of presentation and discussion taking place across three days: 1.WHO’s new initiatives on ageing and health 2.Musculoskeletal health 3.Implementation of the ICOPE approach 4.Emerging themes to strengthen integrated care 5.Updating ICOPE care pathways 6.Multidimensional approach to research on healthy ageing 7.CCHA and GNLTC joint panel: Continuum of integrated care for older people

This policy brief provides an overview of the complexities and challenges of people re-engaging in HIV treatment services. It highlights person-centred interventions that address the reasons for disengagement, the importance of providing support at re-engagement tailored to individual needs and country examples of tracing and re-engagement interventions. The brief summarizes WHO guidance and emphasizes the importance of implementing relevant recommendations to support adherence, continuous engagement, tracing and sustained re-engagement. This brief aims to assist health policy-makers, health ministries, practitioners, implementers and communities to improve understanding of the various challenges and solutions for re-engaging individuals to support better health outcomes. It provides guidance on supporting people living with HIV to sustain re-engagement without further interruptions in treatment and care. The goal is to reduce HIV-related morbidity and mortality, prevent new infections and the risk of drug resistance.

This document is the tenth in a series of Tobacco Knowledge Summaries and is prepared with the objective to summarize the current evidence on the association between tobacco use and HIV. This is also intended as an advocacy tool for the integration of screening for tobacco use, assessing willingness to quit, and offering brief advice, and supporting the initiation of pharmacotherapy as part of standard HIV care practice. This knowledge summary was prepared by the World Health Organization in collaboration with the New York University, School of Global Public Health, and the Global Network of People Living with HIV (GNP+).

The World health statistics report is the annual compilation of health and health-related indicators, which has been published by the World Health Organization since 2005. The 2024 edition reviews more than 50 health-related indicators from the Sustainable Development Goals and WHO’s Thirteenth General Programme of Work. It also highlights the findings from the Global health estimates 2021, notably the impact of the COVID-19 pandemic on life expectancy and healthy life expectancy.

This report is the first of a series of biennial progress reports on the implementation of the Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. It draws attention to areas of progress and gaps in preparation for the mid-term review of the strategies in 2026.

This comprehensive textbook provides an accessible and skills-oriented introduction to alcohol and substance misuse for healthcare students and practitioners new to the field. Divided into five parts, this text explores: The context of alcohol and drug misuse and the nature and theories of addiction, including a historical overview and policy initiatives in contemporary society. An overview of psychoactive substances and the problems associated with them. An exploration of the impact of psychoactive substances on groups, such as culturally and linguistically diverse communities, young people, women, older people, and the homeless. An understanding of the generic role responses to substance misuse in a variety of different settings and contexts, including primary care, the community, and hospitals. A framework for assessment, care planning, harm reduction approaches, dealing with overdose, intoxication and withdrawals, and psychological and pharmacological interventions. This new edition is fully updated and includes expanded coverage of performance-enhancing drugs, e-cigarettes, cannabis use, gender disparities in substance use and treatment, public health approaches to substance use, and screening tools for alcohol misuse. Alcohol and Drug Misuse is enhanced with activities and learning outcomes throughout. It is essential reading for nursing, healthcare, and social work students taking substance misuse modules, as well as related post-registration/qualification courses for health and social care professionals.

This 2024 update of the Provider module for oral and long-acting PrEP of the WHO PrEP Implementation Tool replaces the 2017 Clinical Module. The module integrates clinical service delivery guidance for all three WHO recommended PrEP products (oral PrEP, the dapivirine vaginal ring and long acting injectable cabotegravir). It provides practical support and important considerations for the safe and effective PrEP provision by a range of providers, including physicians, nurses, clinical officers, community health workers, pharmacists and lay and peer providers, in either clinical or community settings.